Clinical Trials Logo

Hepatocellular Carcinoma clinical trials

View clinical trials related to Hepatocellular Carcinoma.

Filter by:

NCT ID: NCT03175679 Recruiting - Clinical trials for Hepatocellular Carcinoma

Adoptive Transfer of iNKT Cells for Treating Patients With Relapsed/Advanced HCC

Start date: May 1, 2017
Phase: Phase 1
Study type: Interventional

This study enrolls patients who have relapsed/advanced hepatocellular carcinoma (HCC, BCLC stage C). The HCC tumor relapsed or metastasized through the body after standard treatment or the patients cannot receive standard treatment under current conditions. This research study uses special immune system cells called iNKT cells, a new experimental treatment. The purpose of this study is to find the biggest dose of iNKT cells that is safe and tolerance, to see how long they last in the body, to learn the immunoresponse in the body, to learn the side effects are and to see if the iNKT cells will help people with relapsed/advanced hepatocellular carcinoma (HCC).

NCT ID: NCT03139487 Recruiting - Pancreatic Cancer Clinical Trials

A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism

PRIORITY
Start date: August 7, 2017
Phase: Phase 2
Study type: Interventional

This is an open label, multi-center, and randomized phase II trial designed to compare the safety and efficacy of direct oral anticoagulants and subcutaneous dalteparin in patients with acute venous thromboembolism and upper gastrointestinal, hepatobiliary, or pancreatic cancer, based on a group sequential design. Enrolled patients will be randomized in a 1:1 ratio. Patients will be stratified by performance status, type of cancer, chemotherapy and medical centers.

NCT ID: NCT03138044 Recruiting - Clinical trials for Hepatocellular Carcinoma

Combined Ipsilateral Liver Lobe Devascularization and Alcohol Treatment of the Large Hepatocellular Carcinoma

Start date: May 20, 2017
Phase: N/A
Study type: Interventional

Assessment of the long-term outcome of combined ipsilateral liver lobe devascularization (ILAD) and alcohol injection of the large hepatocellular carcinoma (HCC): single center non-randomized trial.

NCT ID: NCT03129685 Recruiting - Clinical trials for Hepatocellular Carcinoma

Ipsilateral Liver Lobe Devascularization of the Large Hepatocellular Carcinoma

NRU
Start date: May 20, 2017
Phase: N/A
Study type: Interventional

Assessment of short-term outcomes of ipsilateral lobe arterial devascularization of the large hepatocellular carcinoma: single center non-randomized trial.

NCT ID: NCT03116984 Recruiting - Clinical trials for Hepatocellular Carcinoma

A Study of Comparison of TACE Combination With and Without EBRT for Advanced HCC

TACE-EBRT
Start date: January 1, 2017
Phase: Phase 3
Study type: Interventional

This clinical trial is a prospective, randomized, controlled and multicenter study.And the trial is going to better control intrahepatic tumors for hepatocellular carcinoma(HCC) patients who meet the inclusion criterion.The patients were divided into two groups, the group A by TACE and the other group B by external- beam radiotherapy(EBRT) after 2 times TACE. Then the therapeutic effects and toxicities of TACE and EBRT are evaluated during the follow-up period. The study design plans to enroll 300 patients, and each group includes 150 cases.

NCT ID: NCT03082378 Recruiting - Obesity Clinical Trials

Central Obesity and Hepatocellular Carcinoma

Start date: March 1, 2017
Phase: N/A
Study type: Observational

Recurrence and metastases after microwave ablation(MWA) of hepatocellular carcinoma(HCC) are the major factors that influence the survival. Obesity has been reported was significantly correlated with increased risk of developing HCC. In this study, we will analysis the association of multiple obesity index(waist circumference,waist-hip ratio and body mass index) with the prognosis of HCC treated by MWA.

NCT ID: NCT03081377 Recruiting - Clinical trials for Hepatocellular Carcinoma

Galunisertib (LY2157299) Plus Stereotactic Body Radiotherapy (SBRT) in HCC

Start date: March 29, 2017
Phase: Phase 1
Study type: Interventional

Single arm, open-label to determine the safety and tolerability of galunisertib when combined with SBRT.

NCT ID: NCT03046979 Recruiting - Clinical trials for Hepatocellular Carcinoma

Study of Apatinib in Advanced Hepatocellular Carcinoma(HCC)

HCC
Start date: December 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of apatinib in patients with advanced HCC.

NCT ID: NCT03042520 Recruiting - Diabetes Mellitus Clinical Trials

Long-term Outcomes of Chronic Hepatitis C Patients Post Sofosbuvir-based Treatment

LONGHEAD
Start date: August 2016
Phase:
Study type: Observational

Primary Objective: To evaluate the long-term outcomes including liver related morbidity, mortality and hepatocellular carcinoma (HCC) development as compared to those of historical control with interferon(IFN)-based treatment. Secondary Objective: 1. To access liver fibrosis progression/regression in CHC patients after sofosbuvir-based treatment. 2. To investigate the long-term outcomes of extrahepatic manifestations of the sofosbuvir-based treated cohort as compared to their pretreatment status.

NCT ID: NCT03024684 Recruiting - Clinical trials for HepatoCellular Carcinoma

Statin for Preventing Hepatocellular Carcinoma Recurrence After Curative Treatment

SHOT
Start date: January 3, 2017
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate whether statin could prevent recurrence of hepatocellular carcinoma after curative treatment